PL346975A1 - New crystal modification iii of torasemide - Google Patents
New crystal modification iii of torasemideInfo
- Publication number
- PL346975A1 PL346975A1 PL99346975A PL34697599A PL346975A1 PL 346975 A1 PL346975 A1 PL 346975A1 PL 99346975 A PL99346975 A PL 99346975A PL 34697599 A PL34697599 A PL 34697599A PL 346975 A1 PL346975 A1 PL 346975A1
- Authority
- PL
- Poland
- Prior art keywords
- torasemide
- new
- preparation
- crystal modification
- new crystal
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title abstract 5
- 229960005461 torasemide Drugs 0.000 title abstract 5
- 239000013078 crystal Substances 0.000 title abstract 3
- 230000004048 modification Effects 0.000 title abstract 3
- 238000012986 modification Methods 0.000 title abstract 3
- 230000020477 pH reduction Effects 0.000 abstract 2
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 239000002934 diuretic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Liquid Crystal (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
New crystalline polymorph of torasemide, characterized by its powder x-ray diffraction pattern data; and its preparation by controlled acidification of alkaline torasemide solutions at specific temperatures and over specific periods. New crystal modification (form III) of torasemide, with spacings (d) between lattice planes, expressed in angstroms as 15.3898, 12.5973, 11.4565, 9.7973, 9.5493, 8.6802, 8.2371, 7.6351, 7.3356, 6.9759, 6.5351, 6.3240, 6.1985, 5.9521, 5.6237, 5.5623, 5.4040, 5.1119, 4.8738, 4.7865, 4.6986, 4.5985, 4.4602, 4.3405, 4.2552, 4.1829, 4.0768, 3.9377, 3.8659, 3.8429, 3.7801, 3.7248, 3.6239, 3.5556, 3.4825, 3.4130, 3.3055, 3.2298, 3.1786, 3.1278, 3.0699, 3.0078, 2.9549, 2.9056, 2.8541, 2.7686, 2.6988, 2.6610, 2.6293, 2.5549, 2.5236, 2.4485, 2.4161, 2.3671, 2.3133, 2.2788, 2.2312, 2.1852, 2.1468, 2.0957, 2.0617, 2.0273, 1.9896, 1.9688, 1.9274, 1.8853, 1.7931, 1.7449, 1.7169, 1.6512, 1.6122, 1.5601, 1.5320, 1.5057, 1.4521, and 1.3773. An independent claim is also included for the preparation of this new modification form III, by controlled acidification of an alkaline torasemide solution with inorganic or organic acids, with or without addition of a seed crystal, at a temperature of 0-35[deg]C within a period of 0.25-25 hours. ACTIVITY : Diuretic; cardiovascular; hypotensive; cardiant; ophthalmological; cytostatic; anticonvulsant; antiallergic; antiasthmatic. MECHANISM OF ACTION : None given.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR980532A HRP980532B1 (en) | 1998-10-02 | 1998-10-02 | Novel crystalline torasemide modification |
| PCT/HR1999/000023 WO2000020395A1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL346975A1 true PL346975A1 (en) | 2002-03-11 |
Family
ID=10946825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL99346975A PL346975A1 (en) | 1998-10-02 | 1999-10-01 | New crystal modification iii of torasemide |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US6399637B1 (en) |
| EP (1) | EP1117643B1 (en) |
| JP (1) | JP2002526532A (en) |
| KR (1) | KR100437307B1 (en) |
| CN (1) | CN1125049C (en) |
| AT (1) | ATE286024T1 (en) |
| AU (1) | AU759291B2 (en) |
| BG (1) | BG105485A (en) |
| BR (1) | BR9915018A (en) |
| CA (1) | CA2345789A1 (en) |
| CZ (1) | CZ20011031A3 (en) |
| DE (2) | DE29924789U1 (en) |
| DK (1) | DK1117643T3 (en) |
| EE (1) | EE04341B1 (en) |
| ES (1) | ES2237158T3 (en) |
| HK (1) | HK1040250B (en) |
| HR (1) | HRP980532B1 (en) |
| HU (1) | HUP0104009A3 (en) |
| ID (1) | ID29931A (en) |
| IL (1) | IL142150A0 (en) |
| NO (1) | NO317107B1 (en) |
| NZ (1) | NZ510898A (en) |
| PL (1) | PL346975A1 (en) |
| PT (1) | PT1117643E (en) |
| RU (1) | RU2210569C2 (en) |
| SI (1) | SI1117643T1 (en) |
| SK (1) | SK4232001A3 (en) |
| TR (1) | TR200100909T2 (en) |
| UA (1) | UA72895C2 (en) |
| WO (1) | WO2000020395A1 (en) |
| YU (1) | YU24001A (en) |
| ZA (1) | ZA200102451B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6394707B1 (en) | 1997-05-08 | 2002-05-28 | Jack Kennedy Metal Products & Buildings, Inc. | Yieldable mine roof support |
| HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
| JP2003527319A (en) * | 1999-08-11 | 2003-09-16 | テバ ファーマシューティカル インダストリーズ リミティド | Torsemide polymorph |
| DE10013289A1 (en) * | 2000-03-17 | 2001-09-20 | Knoll Ag | Storage-stable formulations containing diuretic torasemide, are solids or semi-solids containing the active agent in non-crystalline form, e.g. as solid solution in vinyl pyrrolidone polymer matrix |
| HRP20000162B1 (en) | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
| HRP20000328A2 (en) * | 2000-05-19 | 2002-02-28 | Pliva Farmaceutska Ind Dionik | Novel polymorph v of torasemide |
| IN192178B (en) | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
| HRP20020603B1 (en) * | 2002-07-19 | 2008-11-30 | Pliva D.D. | New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide |
| CA2424644A1 (en) * | 2003-04-07 | 2004-10-07 | David John Mckenzie | Preparation of torasemide |
| US20050065183A1 (en) * | 2003-07-31 | 2005-03-24 | Indranil Nandi | Fexofenadine composition and process for preparing |
| PL1750862T3 (en) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Pharmaceutical composition containing irbesartan |
| JP4406845B2 (en) | 2007-02-20 | 2010-02-03 | トヨタ自動車株式会社 | Release agent for secondary battery electrode material and method for treating secondary battery using the release agent |
| EP2705843A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
| CN104370805B (en) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | Torasemide compound |
| CN106038500A (en) * | 2016-05-26 | 2016-10-26 | 南京正科医药股份有限公司 | Torasemide tablet |
| CN115417810B (en) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | Refining method of torsemide crystal form I |
| CN117486789A (en) * | 2023-12-29 | 2024-02-02 | 江西中医药大学 | Torase Mi Gongjing salt and preparation method and application thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| US4055650A (en) * | 1974-04-17 | 1977-10-25 | A. Christiaens Societe Anonyme | Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines |
| US4473693A (en) | 1978-08-04 | 1984-09-25 | Stewart Walter W | Aminonaphthalimide dyes for intracellular labelling |
| DE3529529A1 (en) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | METHOD FOR PRODUCING A STABLE MODIFICATION OF TORASEMIDE |
| US6166041A (en) * | 1995-10-11 | 2000-12-26 | Euro-Celtique, S.A. | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma |
| HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
| US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| US6166045A (en) * | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
-
1998
- 1998-10-02 HR HR980532A patent/HRP980532B1/en not_active IP Right Cessation
-
1999
- 1999-10-01 EP EP99949272A patent/EP1117643B1/en not_active Revoked
- 1999-10-01 BR BR9915018-2A patent/BR9915018A/en not_active IP Right Cessation
- 1999-10-01 TR TR2001/00909T patent/TR200100909T2/en unknown
- 1999-10-01 CZ CZ20011031A patent/CZ20011031A3/en unknown
- 1999-10-01 DE DE29924789U patent/DE29924789U1/en not_active Expired - Lifetime
- 1999-10-01 DK DK99949272T patent/DK1117643T3/en active
- 1999-10-01 UA UA2001031966A patent/UA72895C2/en unknown
- 1999-10-01 EE EEP200100194A patent/EE04341B1/en not_active IP Right Cessation
- 1999-10-01 RU RU2001111831/04A patent/RU2210569C2/en not_active IP Right Cessation
- 1999-10-01 PL PL99346975A patent/PL346975A1/en not_active Application Discontinuation
- 1999-10-01 NZ NZ510898A patent/NZ510898A/en unknown
- 1999-10-01 KR KR10-2001-7004079A patent/KR100437307B1/en not_active IP Right Cessation
- 1999-10-01 IL IL14215099A patent/IL142150A0/en unknown
- 1999-10-01 PT PT99949272T patent/PT1117643E/en unknown
- 1999-10-01 CA CA002345789A patent/CA2345789A1/en not_active Abandoned
- 1999-10-01 WO PCT/HR1999/000023 patent/WO2000020395A1/en active IP Right Grant
- 1999-10-01 HU HU0104009A patent/HUP0104009A3/en unknown
- 1999-10-01 ID IDW20010958A patent/ID29931A/en unknown
- 1999-10-01 SK SK423-2001A patent/SK4232001A3/en not_active Application Discontinuation
- 1999-10-01 ES ES99949272T patent/ES2237158T3/en not_active Expired - Lifetime
- 1999-10-01 SI SI9930744T patent/SI1117643T1/en unknown
- 1999-10-01 JP JP2000574512A patent/JP2002526532A/en active Pending
- 1999-10-01 CN CN99811710A patent/CN1125049C/en not_active Expired - Fee Related
- 1999-10-01 YU YU24001A patent/YU24001A/en unknown
- 1999-10-01 AT AT99949272T patent/ATE286024T1/en not_active IP Right Cessation
- 1999-10-01 ZA ZA200102451A patent/ZA200102451B/en unknown
- 1999-10-01 DE DE69922977T patent/DE69922977C5/en not_active Revoked
- 1999-10-01 AU AU62240/99A patent/AU759291B2/en not_active Ceased
- 1999-11-05 US US09/434,439 patent/US6399637B1/en not_active Expired - Fee Related
-
2001
- 2001-03-30 NO NO20011633A patent/NO317107B1/en unknown
- 2001-05-02 BG BG105485A patent/BG105485A/en unknown
-
2002
- 2002-03-13 US US10/096,277 patent/US6833379B2/en not_active Expired - Fee Related
- 2002-03-15 HK HK02102011.9A patent/HK1040250B/en not_active IP Right Cessation
-
2004
- 2004-06-21 US US10/871,667 patent/US20040229919A1/en not_active Abandoned
-
2006
- 2006-02-21 US US11/357,109 patent/US20060205951A1/en not_active Abandoned
-
2007
- 2007-07-03 US US11/822,274 patent/US20070276015A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL142150A0 (en) | New crystal modification iii of torasemide | |
| CA2360557A1 (en) | Biodegradable and thermosensitive polyphosphazenes and their preparation method | |
| ES8204484A1 (en) | Crystalline 4,1',6'-trichloro-4,1',6'-trideoxy-galactosucrose. | |
| HRP20000092C1 (en) | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof | |
| CA2429228A1 (en) | Improved sucralose composition and process for the crystallization thereof | |
| AU2732395A (en) | A cathode material for lithium secondary batteries and a process and a precursor material for the production thereof | |
| CA2171435A1 (en) | Effervescent granulated material and method for its preparation | |
| WO1997013774A3 (en) | Novel 5-o-deosaminyl 6-o-methyl erythronolide a derivatives, preparation method therefor and use thereof for preparing biologically active materials | |
| AU7829787A (en) | Naphthalene and indan derivatives | |
| MY110352A (en) | Process for preparing 4-demethoxydaunorubicin. | |
| IE800208L (en) | Production of isosorbide-5-nitrate | |
| EP1195356A4 (en) | Composite metal titanate in plate form and method for preparation thereof | |
| CA2089193A1 (en) | Diacetyl production | |
| EP0922704A4 (en) | PROCESS FOR PREPARING 2-(10,11-DIHYDRO-10-OXODIBENZO b,f]THIEPIN-2-YL)PROPIONIC ACID AND INTERMEDIATES THEREFOR | |
| CA2297112A1 (en) | Dicyclanil polymorphs and hydrates and their preparation | |
| CA2252952A1 (en) | Substituted aminomethylphenylsulphonylureas, their preparation, and their use as herbicides and plant growth regulators | |
| Zachwieja | Single Crystal Growth and Structure Refinement of NaAu sub 2--a New Synthesis Method for Alkali Metal--Gold Compounds | |
| Albastroiu | Contributions to the improvement of petroleum coke calcination technology | |
| Cotterill et al. | The stereochemistry and reactions of some 3, 4-disubstituted chromans | |
| JPS5435197A (en) | Preparation of zinc hydroxide platy crystals | |
| Maurer et al. | Process for producing hydroxylapatite | |
| Duboff et al. | Diacetyl production | |
| Wang | The effect of TiO sub 2 addition on the thermal behavior of sol-gel derived beta-spodumene powders | |
| Stepien-Damm et al. | Crystal structure of TbCoSi | |
| EP0287248A3 (en) | A human cell line capable of producing human interleukin 3 having mast cell growth activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |